NOBEL PRIZE 2026
GLOBAL LONGEVITY FRONTIERS
China, Japan, the United States and Europe. A card is a checked source, not a promise that aging can be stopped.
Conceptual illustration of neurons and blue light, made for this site. Not a photograph of an experiment and not a figure from a paper.
China · Animal study
Senescence-resistant cells and FOXO3
Cell, 2025. Lei, Liu and colleagues · 2025-06-13
Lei and colleagues, Cell, 2025, describe human mesenchymal progenitor cells edited at FOXO3 and given intravenously to aged macaques for 44 weeks. It is a non-human primate study, not a human trial and not an approved treatment. Nature Aging later published a highlight of that work. It does not show that human aging is slowed.
https://doi.org/10.1038/s43587-025-00930-1
Conceptual illustration made for this site. Not a photograph of an experiment and not a figure from a paper.
China · Scientific perspective
The X-Age Project: a plan for Chinese aging clocks
Aging Biomarker Consortium · 2025
Li and colleagues, Nature Aging, 2025, volume 5, pages 1669 to 1685. It is a perspective from the Aging Biomarker Consortium: it describes how they intend to build cohorts and biological-age clocks for a Chinese population. It is not a finished clock and not a clinical tool.
China · Animal study
Mechanical force, chromatin and bone in mice
Sichuan University / West China Hospital of Stomatology · 2026-01-13
Liu, Wei and colleagues, Nature Communications, 13 January 2026. In marrow cells and in mice, moderate mechanical stimulation was linked to more chromatin accessibility at FOXO1 and to changes in aged bone. Too much force was linked to DNA damage. Human cells from young and older donors were compared. This is not a treatment trial in people.
China · Scientific review
Aging biomarkers in humans and non-human primates
Aging Biomarker Consortium · 2025-09-11
A review in Nature Reviews Molecular Cell Biology, 11 September 2025, from the Aging Biomarker Consortium, with Guang-Hui Liu as corresponding author. It surveys cellular, tissue and organism markers. It does not report a trial or a treatment.
Japan · Human clinical trial
iPS cells and Parkinson’s: a phase I/II trial
Kyoto University / CiRA and Kyoto University Hospital · 2025-04-16
Sawamoto and colleagues, Nature, 16 April 2025. At Kyoto University Hospital, seven patients aged 50 to 69 received dopaminergic progenitors made from allogeneic iPS cells. The trial is open-label and single-centre (jRCT2090220384). The paper discusses safety and clinical signals in that small group. It is not an approved treatment and not a longevity study.
Conceptual illustration made for this site. Not a photograph of an experiment and not a figure from a paper.
United States · Institutional news release
SenNet and a framework for senescence
National Institutes of Health
An NIH news release on the SenNet consortium, senotypes and an atlas. It calls senolytics experimental. It is an institutional release, not the paper, and not a result showing that clearing senescent cells extends human life.
Conceptual visualization already used on this site. Not a photograph of an experiment and not a figure from a paper.
Europe · Scientific review
From geroscience to precision geromedicine
Kroemer and colleagues, Cell · 2025
Kroemer and colleagues, Cell, 2025. A review of the shift from the study of aging toward what they call precision geromedicine. It does not show that human aging has been stopped or reversed.
RIKEN, The University of Osaka and the National Center for Geriatrics and Gerontology are lines to follow. No extra 2025 or 2026 paper is attached here until the source is checked.